Updated clinical classification of pulmonary hypertension

…, CG Elliott, SP Gaine, MT Gladwin, ZC Jing… - Journal of the American …, 2009 - jacc.org
The aim of a clinical classification of pulmonary hypertension (PH) is to group together different
manifestations of disease sharing similarities in pathophysiologic mechanisms, clinical …

Updated treatment algorithm of pulmonary arterial hypertension

…, A Frost, RE Girgis, J Granton, ZC Jing… - Journal of the American …, 2013 - jacc.org
The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple
and in some ways conflicting. The treatment algorithm usually includes different types of …

A global view of pulmonary hypertension

…, SM Kawut, K Sliwa-Hahnle, ZC Jing… - The Lancet …, 2016 - thelancet.com
Pulmonary hypertension is a substantial global health issue. All age groups are affected
with rapidly growing importance in elderly people, particularly in countries with ageing …

[HTML][HTML] Macitentan and morbidity and mortality in pulmonary arterial hypertension

…, N Galič, HA Ghofrani, P Jansa, ZC Jing… - … England Journal of …, 2013 - Mass Medical Soc
Background Current therapies for pulmonary arterial hypertension have been adopted on the
basis of short-term trials with exercise capacity as the primary end point. We assessed the …

[HTML][HTML] Riociguat for the treatment of pulmonary arterial hypertension

…, E Grünig, M Humbert, ZC Jing… - … England Journal of …, 2013 - Mass Medical Soc
Background Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase
2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this …

Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension

…, JF Cordier, G Habib, V Gressin, ZC Jing… - European …, 2010 - Eur Respiratory Soc
Pulmonary arterial hypertension (PAH) is a progressive, fatal disease. We studied 674
consecutive adult patients who were prospectively enrolled in the French PAH registry (121 …

[HTML][HTML] Risk stratification and medical therapy of pulmonary arterial hypertension

…, RP Frantz, E Grünig, ZC Jing… - European …, 2019 - Eur Respiratory Soc
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability
over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and …

Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers

…, A Marinelli, RJ Barst, HA Ghofrani, ZC Jing… - Journal of the American …, 2006 - jacc.org
Objectives : This study sought to assess the risks associated with right heart catheter
procedures in patients with pulmonary hypertension. Background : Right heart catheterization, …

Clinical features of paediatric pulmonary hypertension: a registry study

…, M Beghetti, T Humpl, GE Raskob, DD Ivy, ZC Jing… - The Lancet, 2012 - thelancet.com
Background Paediatric pulmonary hypertension, is an important cause of morbidity and
mortality, and is insufficiently characterised in children. The Tracking Outcomes and Practice in …

Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial

ZC Jing, K Parikh, T Pulido, C Jerjes-Sanchez… - Circulation, 2013 - Am Heart Assoc
Background— Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no
cure. Parenteral and inhaled prostacyclin analogue therapies are effective for the treatment …